AbbVie Inc.’s (ABBV) investigational orally administered calcitonin gene-related peptide receptor antagonist, Atogepant, proposed for the preventive treatment of migraine in adults, is under FDA review, with a decision expected in late Q3 2021.Calcitonin gene-related peptide (CGRP) and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks and selective CGRP receptor antagonists confer clinical benefit in migraine.Amgen's Aimovig is the first migraine-prevention antibody to be greenlighted by the FDA, which secured approval in 2018. Eli Lilly's Emgality, Teva’s Ajovy and Lundbeck’s Vyepti are some of the other approved drugs for the prevention of migraine in adults.AbbVie’s Atogepant, if approved, could generate peak annual sales of $766 million in 2026, according to GlobalData.ABBV closed Friday’s trading at $119.58, down 0.68%.